- Home
- GUG vs CRVS Comparison
GUG vs CRVS Comparison
Compare GUG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- CRVS
- Stock Information
- Founded
- GUG 2021
- CRVS 2014
- Country
- GUG United States
- CRVS United States
- Employees
- GUG N/A
- CRVS N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GUG Finance
- CRVS Health Care
- Exchange
- GUG Nasdaq
- CRVS Nasdaq
- Market Cap
- GUG 493.4M
- CRVS 516.0M
- IPO Year
- GUG N/A
- CRVS 2016
- Fundamental
- Price
- GUG $15.05
- CRVS $5.29
- Analyst Decision
- GUG
- CRVS Buy
- Analyst Count
- GUG 0
- CRVS 4
- Target Price
- GUG N/A
- CRVS $12.83
- AVG Volume (30 Days)
- GUG 108.9K
- CRVS 1.7M
- Earning Date
- GUG 01-01-0001
- CRVS 11-12-2024
- Dividend Yield
- GUG 9.67%
- CRVS N/A
- EPS Growth
- GUG N/A
- CRVS N/A
- EPS
- GUG N/A
- CRVS N/A
- Revenue
- GUG N/A
- CRVS N/A
- Revenue This Year
- GUG N/A
- CRVS N/A
- Revenue Next Year
- GUG N/A
- CRVS N/A
- P/E Ratio
- GUG N/A
- CRVS N/A
- Revenue Growth
- GUG N/A
- CRVS N/A
- 52 Week Low
- GUG $12.71
- CRVS $1.30
- 52 Week High
- GUG $15.06
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GUG 33.24
- CRVS 34.90
- Support Level
- GUG $14.90
- CRVS $4.52
- Resistance Level
- GUG $15.28
- CRVS $5.34
- Average True Range (ATR)
- GUG 0.28
- CRVS 0.63
- MACD
- GUG -0.04
- CRVS -0.31
- Stochastic Oscillator
- GUG 16.29
- CRVS 32.20
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).